Meyka AI API is live for developers.Start building.
Advertisement
REGENXBIO Inc.

REGENXBIO Inc. (RGNX) Stock Overview

Explore REGENXBIO Inc.’s financial performance, market position, analyst ratings, and future outlook.

RGNXNASDAQ
HealthcareBiotechnology
$6.08
$0.80(11.63%)
U.S. Market opens in 64h 1m
Advertisement

REGENXBIO Inc. (RGNX)

Meyka AI Score

Z

Key Financials

Market Cap314.3M
P/E Ratio-1.25
EPS (TTM)$-5.60
ROE-2.32%
Fundamental Analysis

AI Price Forecasts

1 Month$9.35
3 Months$11.01
1 Year Target$10.80

RGNX Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of REGENXBIO Inc. (RGNX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 44.00, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $10.80.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.25 and a market capitalization of 314.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
-11.63%
5-Day Change
-13.64%
1-Month Change
-34.06%
3-Month Change
-30.28%
6-Month Change
-53.80%
Year-to-Date (YTD) Change
-57.78%
1-Year Change
-27.27%
3-Year Change
-68.37%
5-Year Change
-83.74%
All-Time (Max) Change
-80.03%

Contact Information

240 552 8181
9804 Medical Center Drive, Rockville, MD, 20850

Company Facts

353 Employees
IPO DateSep 17, 2015
CountryUS
Actively Trading

Frequently Asked Questions